Obesity drug Wegovy cut risk of serious heart problems by 20%, study findsThe findings could shift perceptions that the new class of obesity drugs are cosmetic treatments and put pressure on health insurers to cover them. Publicly funded genetic test for suitable antidepressants would save healthcare costs: studyGenes are responsible for about 42% of the variation in how people respond to antidepressants. Older Canadians take more prescription opioids than any other age group: report Older adults also more vulnerable to overdosing, hospitalization and death from them. Tool helps pharmacists and physicians see interactions between cannabinoids and other medications The free CANNabinoid Drug Interaction Review allows pharmacists and other healthcare professionals to quickly see if there is a potential interaction. Polypharmacy rising among seniors with heart failure Quebecers aged 65 and over with heart failure are taking more and more different pharmacological treatments, according to a new study What happens when drugs don’t have to be tested on people who are obese More than 40% of American adults are considered obese, yet the medications many take are rarely tested in bigger bodies. U.S. FDA approves new version of diabetes drug Mounjaro for weight loss Zepbound is the latest diabetes drug approved for weight loss, joining Novo Nordisk’s Wegovy, a high-dose version of its diabetes treatment Ozempic. Once-weekly Mounjaro now available in Canada for treatment of type 2 diabetes Tirzepatide, the first “twincretin,” reduces A1C and body weight in adults with type 2 diabetes. Canadian antiplatelet guidelines update: changes include no ASA for routine primary prevention of cardiac disease Other changes include recommendations for de-escalation of dual antiplatelet therapy in select patients and dual antiplatelet therapy post-CABG. Drug news—October 2023 A review of new launches, new indications, new dosage forms and Health Canada advisories. First Previous 18 19 20 21 22 Next Last
